The biopharmaceutical company co-founded by convicted stock fraudster Martin Shkreli has lost its bid to depose the executive of a generic pharmaceutical company in connection with an antitrust lawsuit, and a Philadelphia federal judge has ordered it to pay the executive’s legal bill.

U.S. District Judge J. Curtis Joyner of the Eastern District of Pennsylvania granted a motion to quash a subpoena issued by Retrophin, in which the company sought to depose an executive at Prinston Pharmaceuticals. The ruling was handed up Wednesday, and docketed with the court Thursday.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]